On April 7, 2022, ILIAS Biologics, Inc., a biotech company dedicated to developing a new treatment modality, engineered exosome therapeutics, announced that it has received approval by the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1, first-in-human trial of ILB-202, an exosome therapeutic for the treatment of cardiac surgery-associated acute kidney injury (CSA-AKI). ILIAS is the first Korean company to enter a global clinical trial for exosome-based therapeutics. The study will evaluate the safety and tolerability of ILB-202 in healthy adult volunteers. ILB-202, containing the anti-inflammatory protein super-repressor lκB (srlκB), can attenuate inflammatory responses in various disease models through the introduction of srlκB, the dominant active form of lκBα, by inhibiting the translocation of NF-κB into the nucleus. ILIAS has developed ILB-202 using the company’s platform technology, EXPLOR® (Exosomes engineering for Protein Loading via Optically Reversible protein-protein interaction).
Login Or Register To Read Full Story